This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. S Articles by Peters, B. S Search for Related Content Social Bookmarking                         What's this?

Review: Clinical aspects of the management of HIV lipodystrophy

Department of Chemical Pathology, St. Thomas' Hospital, London, UK, Anthony.Wierzbicki{at}kcl.ac.uk

Scott D Purdon

Department of Patient Relations, Pharmaceuticals International, GlaxoSmithKline, Brentford, Middlesex, UK

Timothy C Hardman

Niche Science & Technology Ltd, 96 Wolsey Drive, Kingston-Upon-Thames, Surrey, UK

Ranjababu Kulasegaram

HIV Unit, Harrison Wing, St. Thomas' Hospital, London, UK

Barry S Peters

HIV Unit, Harrison Wing, St. Thomas' Hospital, London, UK

Chronic complications of human immunodeficiency virus (HIV) and highly active retroviral therapy have become increasingly relevant as life expectancy for HIV patients has improved and the affected population ages. HIV-associated lipodystrophy syndrome is characterised by an abnormal fat distribution syndrome associated with metabolic disturbances including insulin resistance, and deranged glucose and lipid metabolism. It is associated with increased risks of progression to type 2 diabetes and cardiovascular disease.

Lipodystrophy is a clinical diagnosis and mostly subjective as standardised diagnostic criteria have not yet been defined. Several therapeutic interventions have been investigated including lifestyle therapy, vitamin supplements, switching antiretroviral therapy and specific therapies for insulin resistance and hyperlipidaemia. Current management options for HIV associated lipodystrophy are limited and are mostly based on avoidance of risk factors and switching of antiretroviral drugs. Therapies to improve insulin resistance have been tried but they are frequently ineffective as are lipid-lowering drugs. Interest in anabolic agents has been resurrected and new clinical data suggest that HIV-associated lipodystrophy growth hormone releasing factor therapy may have a beneficial role in the treatment of HIV-associated lipodystrophy. However, there still remains a need for robust prospective cohort studies and well designed intervention trials to resolve the aetiology and define the best treatment for this complication of HIV disease and its treatment.

Key Words: cardiovascular risk • cholesterol • diabetes • human immunodeficiency virus • lipodystrophy • treatment • triglycerides.

References

• Lohse N., Hansen AB, Pedersen G. et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.[Abstract/Free Full Text]
• Bozzette SA, Ake CF, Tam HK et al. Cardiovascular Rand cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.[Abstract/Free Full Text]
• World Health Organisation and Joint United Nations Programme on HIV/AIDS. Treating 3 million by 2005: making it happen, the WHO strategy. Geneva: World Health Organisation; 2003.
• Carr A., Samaras K., Chisholm DJ et al. Pathogen ( esis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carr A., Samaras K., Thorisdottir A. et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001;2:166-73.[CrossRef][Medline] [Order article via Infotrieve]
• Wierzbicki AS, Purdon SD, Hardman TC et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 2008;24:609-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Milinkovic A., Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother 2005;56:6-9.[Abstract/Free Full Text]
• Grunfeld C., Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003;37(suppl 2):S43-S46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carr A., Samaras K., Burton S. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saint-Marc T., Partisani M., Poizot-Martin I. et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Behrens GM, Stoll M., Schmidt RE Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23(1):57-76.[Medline] [Order article via Infotrieve]
• Hakeem L., Campbell IW, Bhattacharyya DP HIV-associated lipodystrophy - a new metabolic syndrome. Br J Diabetes Vasc Dis 2008; 8:129-34.[Abstract/Free Full Text]
• Wanke CA, Falutz JM, Shevitz A. et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002;34:248-59.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Justman JE, Benning L., Danoff A. et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32:298-302.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Paparizos VA, Kyriakis KP, Botsis C. et al. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000;14:903-05.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sharp M. Metabolic complications associated with HIV disease. Posit Aware 2003;14(2):32-6.[Medline] [Order article via Infotrieve]
• Kulasegaram R., Peters BS, Wierzbicki AS Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005;21:1717-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
• Mondy K., Overton ET, Grubb J. et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30 Suppl 2:S135-S142.
• Heath KV, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Galli M., Ridolfo AL, Adorni F. et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29(1):21-31.[Web of Science][Medline] [Order article via Infotrieve]
• Heath KV, Hogg RS, Singer J. et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a populatio-based chort. J Acquir Immune Defic Syndr 2002;30:440-7.[Web of Science][Medline] [Order article via Infotrieve]
• Grinspoon SK Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005;118 (suppl 2):S23-S28.[CrossRef][Medline] [Order article via Infotrieve]
• Carr A., Samaras K., Thorisdottir A. et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kotler DP, Thea DM, Heo M. et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr 1999;69:432-9.[Abstract/Free Full Text]
• Jaya G., Lutchman N., Crowther N. Metabolic Complications of ART in Black South Africans. 14th Conference on Retrovirus' and Opportunistic Infections Los Angeles USA 2007 Abstract 796
• Saves M., Raffi F., Capeau J. et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Maisonneuve C., Igoudjil A., Begriche K. et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther 2004;9:801-10.[Web of Science][Medline] [Order article via Infotrieve]
• Haubrich RH, Riddler S., diRienzo G. et al. Metabolic outcomes of ACTG 5142: a prospective, randomised, phase III trial of NRTI-, PI-, and NNRTI-sparing regimes for initial treatment of HIV-1 infection 2007.
• Cameron DW, da Silva B., Arribas J. et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV/3TC. 2007.
• Grunfeld C., Pang M., Doerrler W. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.[Abstract]
• Badiou S., De Boever CM, Dupuy AM et al. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen. AIDS 2003;17:772-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.[Abstract/Free Full Text]
• Lafeuillade A., Alessi MC, Poizot-Martin I. et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992;5:127-31.[Web of Science][Medline] [Order article via Infotrieve]
• Seminari E., Pan A., Voltini G. et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mercie P., Thiebaut R., Lavignolle V. et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34(1):55-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Purnell JQ, Zambon A., Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14(1):51-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks. J Assoc Nurses AIDS Care 2002;13(2):86-7.[Medline] [Order article via Infotrieve]
• Noor MA, Parker RA, O'Mara E. et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIVseronegative healthy adults. AIDS 2004;18:2137-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sanne I., Piliero P., Squires K. et al. Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects. J Acquir Immune Defic Syndr 2003;32(1):18-29.[Web of Science][Medline] [Order article via Infotrieve]
• Penzak SR, Chuck SK Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Martinez E., Garcia-Viejo MA, Blanco JL et al. Impact of switching from HIV type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Piketty C., Peytavin G., Trylezinski A. et al. Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. HIV Med 2002;3:287-9.[CrossRef][Medline] [Order article via Infotrieve]
• Martinez E., Arnaiz JA, Podzamczer D. et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with huma immunodeficiency virus infection. N Engl J Med 2003;349:1036-46.[Abstract/Free Full Text]
• Behrens G., Dejam A., Schmidt H. et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Murata H., Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4.[Abstract/Free Full Text]
• Carpentier A., Patterson BW, Uffelman KD et al. Mechanism of highly active antiretroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005;178:165-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lucas GM, Chaisson RE, Moore RD Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003:33:321-8.[Web of Science][Medline] [Order article via Infotrieve]
• Brambilla AM, Novati R., Calori G. et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003;17:1993-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005;118(suppl 2):3S-8S.
• Gerschenson M., Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004;4:763-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fleischman A., Johnsen S., Systrom D. et al. Effects of NRTI, stavudine, on insulin sensitivity and mitochondrial function in muscle of healthy adults. 14th Conference on Retrovirus' and Opportunistic Infections Los Angeles USA 2007 Abstract 43.
• Birkus G., Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.[Abstract/Free Full Text]
• Lee H., Hanes J., Johnson KA Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis W., Dalakas MC Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lichtenstein KA Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005;39:395-400.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carr A., Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571-6.[Web of Science][Medline] [Order article via Infotrieve]
• Sheridan S., Pignone M., Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003;18:1039-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Derivatioon and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.[Abstract/Free Full Text]
• Hanley AJ, Karter AJ, Williams K. et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112:3713-21.[Abstract/Free Full Text]
• Wilson PW, Meigs JB, Sullivan L. et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74.[Abstract/Free Full Text]
• Roubenoff R., Schmitz H., Bairos L. et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002;34:390-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Orchard TJ, Temprosa M., Goldberg R. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-19.[Abstract/Free Full Text]
• Wierzbicki AS Low HDL-cholesterol: Common and under-treated, but which drug to use? Int J Clin Pract 2006;60:1149-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brinkman K., ter Hofstede HJ, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.[Web of Science][Medline] [Order article via Infotrieve]
• Saint-Marc T., Partisani M., Poizot-Martin I. et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14(1):37-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Safrin S., Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Martinez E., Conget I., Lozano L. et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Opravil M., Hirschel B., Lazzarin A. et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis 2003;36(Suppl 2):S84-S90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lindström J., Ilanne-Parikka P., Peltonen M. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hadigan C., Corcoran C., Basgoz N. et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-7.[Abstract/Free Full Text]
• Blazes DL, Decker CF Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy. Lancet Infect Dis 2006;6:249-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gavrila A., Hsu W., Tsiodras S. et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomised, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Prasithsirikul W., Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thai 2004;87:166-72.[Medline] [Order article via Infotrieve]
• Sutinen J., Hakkinen AM, Westerbacka J. et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207.[Medline] [Order article via Infotrieve]
• Sheffield CA, Kane MP, Busch RS Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy 2007;27:1449-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fichtenbaum CJ, Gerber JG Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mallon PW, Miller J., Kovacic JC et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men -a randomized, placebo-controlled study. AIDS 2006;20:1003-10.[Web of Science][Medline] [Order article via Infotrieve]
• Badiou S., Merle De BC, Dupuy AM et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nystrom T., Bratt G., Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med 2002;252:570-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dube MP, Wu JW, Aberg JA et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11:1081-9.[Web of Science][Medline] [Order article via Infotrieve]
• Samson SL, Pownall HJ, Scott LW et al. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials 2006;27:518-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lee JH, Chan JL, Sourlas E. et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605-11.[Abstract/Free Full Text]
• Benavides S., Nahata MC Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004;38:448-57.[Abstract/Free Full Text]
• Mulligan K., Grunfeld C., Hellerstein MK et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.[Abstract]
• Wanke C., Gerrior J., Kantaros J. et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schwarz JM, Mulligan K., Lee J. et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87:942.[Abstract/Free Full Text]
• Falutz J., Allas S., Blot K. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 3, 113-119 (2008)
DOI: 10.1177/14746514080080030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Hakeem, I. W Campbell, and D. N. Bhattacharyya HIV-associated lipodystrophy - a new metabolic syndrome The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 129 - 134. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. S Articles by Peters, B. S Search for Related Content Social Bookmarking                         What's this?